Format

Send to

Choose Destination
Med Arh. 2004;58(1):11-3.

[Effectiveness of gemcitabine in combination with cisplatin in a randomized study of untreated patients with advanced non-small-cell lung carcinoma].

[Article in Bosnian]

Author information

1
Klinika za plućne bolesti i tuberkulozu, Klinicki centar Univerziteta u Sarajevu.

Abstract

Lung cancer is the leading cause of cancer death in men worldwide. It accounts for 29 percent of all cancer deaths in men in the European community; the corresponding figure for woman is 9 percent.

AIMS:

The evaluation Response Rate (RR) and one-year survival in inoperable locally advanced Non-Small cell Lung Cancer (NSCLC) treated with Gemcitabine (Gemzar/kappa) plus Cisplatin and fractionated chest radiation. The evaluation RR and one-year survival in metastatic NSCLC treated with Gemcitabine plus Cisplatin.

PATIENTS AND METHODS:

Retrospective clinical study on two years clinical material (2000 and 2001). In first group number of evaluated patients was 74 with stage IIIa (N2) and IIIb; mean age 52.5; male 56, female 18; WHO performance status 0-2. Second group was 14 patients with stage IV and next characteristics: mean age 50.3; male 10, female 4; WHO performance status 0-2. Treatment schedule for patients with stage IIIa (N2) and IIIb: Cisplatin 75 mg/m2 plus Gemcitabin 1250 mg/m2, day first, and Gemcitabin 1250 mg/m2, day 8, every 3 weeks, total 3 cycles. After third cycle chemotherapy, in period from 7-14 days started with fractionated radiation therapy. Usually it was 40-46 Gy on tumor and mediastinum during 30 days. Patients with metastatic NSCLC (stage IV) treated with the same schedule, every three weeks, total 4 cycles but without fractionated radiation therapy.

RESULTS:

Overall RR for stage IIIa (N2) and stage IIIb was 46.6% and one-year survival 42.5%. RR for stage IV was in the form of partial response at the eight patients (57%) with one-year survival 7.3% (one patient) and median time to disease progression 1.3 months.

CONCLUSION:

In our two years clinical sample we treated 74 patients with NSCLC stage IIIa (N2) and stage IIIb with schedule--Cisplatin 75 mg/m2 plus Gemcitabin 1250 mg/m2, day first, and Gemcitabin 1250 mg/m2, day 8, every 3 weeks, total 3 cycles and fractionated radiation therapy with 40-46 Gy during 30 days on tumor and mediastinum. It's very effective regime with overall response rate 46.6% and one-year survival 42.5%. For stage IV it's not so effective regime, because, even now, it's so expensive regime for us.

PMID:
15017896
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center